BTIG Research reissued their buy rating on shares of Integra Lifesciences (NASDAQ:IART) in a research report report published on Wednesday, September 12th. They currently have a $69.00 price objective on the life sciences company’s stock.
Several other research firms also recently commented on IART. Zacks Investment Research downgraded shares of Integra Lifesciences from a buy rating to a hold rating in a research report on Tuesday, June 26th. Cantor Fitzgerald reissued a hold rating and set a $59.00 target price on shares of Integra Lifesciences in a research report on Wednesday, July 25th. BidaskClub downgraded shares of Integra Lifesciences from a strong-buy rating to a buy rating in a research report on Thursday, July 12th. Oppenheimer reissued a buy rating on shares of Integra Lifesciences in a research report on Friday, August 17th. Finally, Bank of America cut shares of Integra Lifesciences from a neutral rating to an underperform rating in a report on Tuesday, August 7th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $61.38.
IART stock traded down $0.16 during midday trading on Wednesday, hitting $61.26. The stock had a trading volume of 505,500 shares, compared to its average volume of 727,145. Integra Lifesciences has a 1-year low of $41.51 and a 1-year high of $67.50. The company has a quick ratio of 2.27, a current ratio of 3.52 and a debt-to-equity ratio of 1.10. The firm has a market cap of $5.61 billion, a price-to-earnings ratio of 31.47, a PEG ratio of 2.03 and a beta of 0.57.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 25th. The life sciences company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. Integra Lifesciences had a net margin of 5.10% and a return on equity of 17.43%. The firm had revenue of $366.20 million during the quarter, compared to the consensus estimate of $368.08 million. During the same period in the previous year, the firm posted $0.45 earnings per share. The business’s revenue was up 29.8% compared to the same quarter last year. Research analysts expect that Integra Lifesciences will post 2.4 earnings per share for the current year.
In related news, VP Glenn Coleman sold 8,916 shares of the company’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $63.00, for a total transaction of $561,708.00. Following the sale, the vice president now directly owns 16,795 shares in the company, valued at approximately $1,058,085. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stuart Essig sold 159,752 shares of the company’s stock in a transaction that occurred on Tuesday, July 10th. The shares were sold at an average price of $64.01, for a total transaction of $10,225,725.52. Following the sale, the director now owns 1,539,019 shares in the company, valued at $98,512,606.19. The disclosure for this sale can be found here. Over the last quarter, insiders sold 270,892 shares of company stock worth $17,280,372. Corporate insiders own 5.10% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Paloma Partners Management Co bought a new stake in Integra Lifesciences during the 2nd quarter worth approximately $12,012,000. GSA Capital Partners LLP bought a new stake in Integra Lifesciences during the 2nd quarter worth approximately $538,000. Bank of Montreal Can increased its holdings in shares of Integra Lifesciences by 55.8% in the 2nd quarter. Bank of Montreal Can now owns 16,018 shares of the life sciences company’s stock worth $1,031,000 after buying an additional 5,739 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Integra Lifesciences by 12.1% in the 2nd quarter. Sei Investments Co. now owns 179,756 shares of the life sciences company’s stock worth $11,578,000 after buying an additional 19,377 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of Integra Lifesciences by 2.1% in the 1st quarter. Principal Financial Group Inc. now owns 494,735 shares of the life sciences company’s stock worth $27,379,000 after buying an additional 10,388 shares during the last quarter. 84.41% of the stock is currently owned by institutional investors and hedge funds.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Article: What Factors Can Affect Return on Equity?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.